📅 2026 FDA PDUFA Calendar Highlights a Pivotal Year for Rare Disease Innovation
Beyond headline approvals, the FDA’s 2026 calendar underscores how far the rare disease pipeline has come—especially in cell and gene therapy. A number of key orphan drug decisions will shape the year ahead, reflecting the culmination of over a decade of translational research and regulatory progress.
🔹 Key pending approvals:
- Idebenone – Leber hereditary optic neuropathy (LHON) from @Chiesi | Feb 28
- TransCon CNP (navepegritide) – Achondroplasia from @Ascendis Pharma | Feb 28
- Palynziq (pegvaliase) – Phenylketonuria from @BioMarin | Feb 28
- Linerixibat – Primary biliary cholangitis – from @GSK | Mar 24
- Kresladi (marnetegragene autotemcel) – LAD-I from @Rocket Pharmaceuticals | Mar 28
- Tividenofusp alfa – Hunter syndrome from @Denali Therapeutics | Apr 5
- Orca-T – AML, ALL, and myelodysplastic syndromes from @Orca Bio | Apr 6
- FILSPARI (sparsentan) – Focal segmental glomerulosclerosis (FSGS) from @Travere Therapeutics | Apr 13
This concentration of PDUFA dates highlights the steady maturation of the rare disease ecosystem— the convergence of advanced R&D, digital data integration, and stronger regulatory clarity.
At Clinakos, we continue to explore how real-world data and intelligent analytics can support evidence generation, accelerate development timelines, and ultimately improve patient access to these therapies.
Source: https://checkrare.com/2026-orphan-drugs-pdufa-dates-and-fda-approvals/
Learn more about what we do at https://clinakos.com
